Thiopurines in current medical practice: Molecular mechanisms and contributions to therapy-related cancer

Nature Reviews Cancer

Volumn 8, Issue 1, 2008, Pages 24-36

  Karran, Peter ^a   Attard, Natalie ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 MERCAPTOPURINE DERIVATIVE; AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; AUTOIMMUNE DISEASE; BASAL CELL CARCINOMA; CANCER GROWTH; CANCER RISK; CHRONIC INFLAMMATION; CLINICAL DECISION MAKING; COLORECTAL CANCER; ENTERITIS; HEPATOBILIARY SYSTEM CANCER; HIGH RISK PATIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; MEDICAL PRACTICE; MESENCHYMOMA; NONHODGKIN LYMPHOMA; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SKIN CANCER; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; SYSTEMIC LUPUS ERYTHEMATOSUS;

6-MERCAPTOPURINE; ANTINEOPLASTIC AGENTS; AZATHIOPRINE; CARCINOGENS; CELL SURVIVAL; HUMANS; NEOPLASMS; PURINES; SULFHYDRYL COMPOUNDS; THIOGUANINE;

EID: 37549024231     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2292     Document Type: Review

References (102)

1. Flowers, C. R. & Melmon, K. L. Clinical investigators as critical determinants in pharmaceutical innovation. Nature Med. 3, 136-143 (1997).
2. Azathioprine. IARC Monographs 26 (Suppl. 7), 119 (1987).
3. Smith, C. et al. AIDS-related malignancies. Ann. Med. 30, 323-344 (1998).
4. Grulich, A. E., van Leeuwen, M. T., Falster, M. O. & Vajdic, C. M. Incidence of cancers in people with HIV/ AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370, 59-67 (2007).
5. Harwood, C. A. et al. Increased risk of skin cancer associated with the presence of epidermodysplasia verruciformis human papillomavirus types in normal skin. Br. J. Dermatol. 150, 949-957 (2004).
6. Clarke, D. A. et al. 6-Mercaptopurine: effects in mouse sarcoma 180 and in normal animals. Cancer Res. 13, 593-604 (1953).
7. Burchenal, J. H. et al. Clinical evaluation of a new metabolite, 6-mercaptopurine, in the treatment of leukaemia and allied diseases. Blood 8, 965-999 (1953).
8. Remuzzi, G. et al. Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet 364, 503-512 (2004).
9. Brennan, D. C. & Koch, M. J. Is mycophenolate mofetil really necessary in renal transplantation? A review of the MYSS follow-up study. Nature Clin. Pract. 3, 602-603 (2007).
10. Taylor, A. L., Watson, C. J. E. & Bradley, J. A. Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy. Crit. Rev. Oncol. Haematol. 56, 23-46 (2005).
11. Bean, R. H. D. Treatment of ulcerative colitis with antimetabolites. Br. Med. J. 1, 1081-1084 (1966).
12. Connell, W. R., Kamm, M. A., Ritchie, J. K. & Lennard-Jones, J. E. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 34, 1081-1085 (1993).
13. Aarbakke, J., Janka-Schaub, G. & Elion, G. B. Thiopurine biology and pharmacology. Trends Pharmacol. Sci. 18, 3-8 (1997).
14. Fotoohi, A. K., Lindquist, M., Peterson, C. & Albertoni, F. Involvement of the concentrative nucleoside transporter 3 and equilibrative nucleoside transporter 2 in the resistance of T-lymphoblastic cell lines to thiopurines. Biochem. Biophys. Res. Commun. 343, 208-215 (2006).
15. Wang, L. & Weinshilboum, R. Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene 25, 1629-1638 (2006). An excellent review of the properties, regulation and genetics of TPMT and the implications of this information for clinical practice.
16. Krynetski, E. & Evans, W. E. Drug methylation in cancer therapy: lessons from the TPMT polymorphism. Oncogene 22, 7403-7413 (2003).
17. Ranjard, L., Prigent-Combaret, C., Nazaret, S. & Cournoyer, B. Methylation of inorganic and organic selenium by the bacterial thiopurine methyltransferase. J. Bacteriol. 184, 3146-3149 (2002).
18. Krynetski, E. Y., Krynetskaia, N. F., Yanishevski, Y. & Evans, W. E. Methylation of mercaptopurine, thioguanine, and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase. Mol. Pharmacol. 47, 1141-1147 (1995).
19. Marshall, E. Preventing toxicity with a gene test. Science 302, 588-590 (2003).
20. Yoshida, S., Yamada, M., Masaki, S. & Saneyoshi, M. Utilization of 2′-deoxy-6-thioguanosine 5′-triphosphate in DNA synthesis in vitro by DNA polymerase α from calf thymus. Cancer Res. 39, 3955-3958 (1979).
21. Ling, Y. H., Nelson, J. A., Cheng, Y. C., Anderson, R. S. & Beattie, K. L. 2′-Deoxy-6-thioguanosine 5′-triphosphate as a substrate for purified human DNA polymerases and calf thymus terminal deoxynucleotidyltransferase in vitro. Mol. Pharmacol. 40, 508-514 (1991).
22. Zhang, X. et al. Novel DNA lesions generated by the interaction between therapeutic thiopurines and UVA light. DNA Repair 6, 344-354 (2006).
23. Rappaport, H. P. Replication of the base pair 6-thioguanine/5-methyl-2- pyrimidone with the large Klenow fragment of Escherichia coli DNA polymerase I. Biochemistry 32, 3047-3057 (1993).
24. Tidd, D. M. & Paterson, A. R. P. Distinction between inhibition of purine nucleotide synthesis and the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res. 34, 733-737 (1974).
25. 2-M arrest in MMR-proficient RKO cells. Clin. Cancer Res. 9, 2327-2334 (2003).
26. Roberts, J. J., Pascoe, J. M., Plant, J. E., Sturrock, J. E. & Crathorn, A. R. Quantitative aspects of the repair of alkylated DNA in cultured mammalian cells. I. The effect on HeLa and Chinese hamster cell survival of alkylation of cellular macromolecules. Chem. Biol. Interact. 3, 29-47 (1971). The first in a series of detailed studies of the effects of methylating agents on the cell cycle and on survival. These papers were influential in the development of the 'futile processing' model of mismatch repair intervention at DNA damage.
27. Zhukovskaya, N., Branch, P., Aquilina, G. & Karran, P. DNA replication arrest and tolerance to DNA methylation damage. Carcinogenesis 15, 2189-2194 (1994).
28. Karran, P. & Bignami, M. DNA damage tolerance, mismatch repair and genome instability. BioEssays 16, 833-839 (1994).
29. 6- methylguanine and 6-thioguanine cytotoxic effects: a cross-resistant phenotype in N-methylnitrosourea-resistant Chinese hamster ovary cells. Cancer Res. 50, 4248-4253 (1990). This paper makes the important connection between resistance to methylating agents and to thiopurines and suggests that these share a common underlying mechanism.
30. Koi, M. et al. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N′-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res. 54, 4308-4312 (1994).
31. 6-methylguanine in bacteria.
32. 4- alkylthymine and the mutagenic properties of these bases. Mutat. Res. 233, 81-94 (1990).
33. 2 cell cycle checkpoint. Cancer Res. 55, 3721-3725 (1995).
34. N1-type methylating agents requires the ATR kinase. Genes Dev. 18, 1331-1344 (2004). The first careful examination of the molecular signalling events downstream of mismatch repair processing of DNA methylation damage.
35. 6-methylguanine adducts. Mol. Cell 22, 501-510 (2006).
36. Adamson, A. W., Kim, W.-J., Shangary, S., Baskaran, R. & Brown, K. D. ATM is activated in response to N-methyl-N′-nitro-N- nitrosoguanidine-induced DNA alkylation. J. Biol. Chem. 277, 38222-38229 (2002).
37. N1 type methylating agents activate DNA damage signaling cascades that are largely independent of mismatch repair. Cell Cycle 4, 473-477 2005).
38. Zou, L. & Elledge, S. J. Sensing DNA damage through ATRIP recognition of RPA-ssDNA complexes. Science 300, 1542-1548 (2003).
39. 6-methylguanine lesions in human nuclear extracts. J. Biol. Chem. 281, 22674-22683 (2006). This paper provides the first direct biochemical evidence in support of the futile processing cycle model of methylation tolerance.
40. 6-methylguanine DNA adducts on the adenosine nucleotide switch functions of hMSH2-hMSH6 and hMSH2-hMSH3. J. Biol. Chem. 275, 27851-27857 (2000).
41. + and methylation-tolerant mismatch repair compromised cells: facts and models. Mutat. Res. 381, 227-241 (1997).
42. Vernole, P., Pepponi, R. & d'Atri, S. Role of mismatch repair in the induction of chromosomal aberrations and sister chromatid exchanges in cells treated with different chemotherapeutic agents Cancer Chemother. Pharmacol. 52, 185-192 (2003).
43. Abdel-Rahman, W. M., Mecklin, J. P. & Peltomäki, P. The genetics of HNPCC: application to diagnosis and screening. Crit. Rev. Oncol. Hematol. 58, 208-220 (2006).
44. Swann, P. F. et al. Role of post-replicative DNA mismatch repair in the cytotoxic action of thioguanine. Science 273, 1109-1111 (1996). The first demonstration that the chemically favoured S-methylation of DNA 6-TG was important for its interaction with mismatch repair.
45. Xu, Y.-Z., Zheng, Q. & Swann, P. F. Synthesis by post-synthetic substitution of oligomers containing guanine modified at the 6-position with S- N-, O-derivatives. Tetrahedron 48, 1729-1742 (1992).
46. Rydberg, B. & Lindahl, T. Nonenzymatic methylation of DNA by the intracellular methyl group donor S-adenosyl-L-methionine is a potentially mutagenic reaction. EMBO J. 1, 211-216 (1982).
47. Bodell, W. J. Investigation of 6-thiodeoxyguanosine alkylation products and their role in the potentiation of BCNU cytotoxicity. IARC Sci. Pub. 70, 147-154 (1986).
48. Branch, P., Aquilina, G., Bignami, M. & Karran, P. Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature 362, 652-654 (1993).
49. Offman, J. et al. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood 104, 822-828 (2004).
50. Fotoohi, A. K., Lindquist, M., Peterson, C. & Albertoni, F. Impaired transport as a mechanism of resistance to thiopurines in human T-lymphoblastic leukemia cells. Nucleosides Nucleotides Nucleic Acids 25, 1039-1044 (2006).
51. Krynetski, E. Y., Krynetskaia, N. F., Gallo, A. E., Murti, K. G. & Evans, W. E. A novel protein complex distinct from mismatch repair binds thioguanylated DNA. Mol. Pharmacol. 59, 367-374 (2001).
52. Krynetski, E. Y., Krynetskaia, N. F., Bianchi, M. E. & Evans, W. E. A nuclear protein complex containing high mobility group proteins B1 and B2, heat shock cognate protein 70, ERp60, and glyceraldehyde-3-phosphate dehydrogenase is involved in the cytotoxic response to DNA modified by incorporation of anticancer nucleoside analogs. Cancer Res. 63, 100-106 (2003).
53. Tay, B. S., Lilley, R. M., Murray, A. W. & Atkinson, M. R. Inhibition of phosphoribosyl pyrophosphate amidotransferase from Ehrlich ascites-tumour cells by thiopurine nucleotides. Biochem. Pharmacol. 18, 936-938 (1969).
54. Relling, M. V. et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J. Natl Cancer Inst. 91, 2001-2008 (1999).
55. Lennard, L. Therapeutic drug monitoring of antimetabolic cytotoxic drugs. Br. J. Clin. Pharmac. 47, 131-143 (1999).
56. Lennard, L., van Loon, J. A. & Weinshilboum, R. M. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin. Pharmacol. Ther. 46, 149-154 (1989). One of several important papers by these authors drawing attention to the importance of thioguanine nucleotides and thiopurine S-methyltransferase levels in myelotoxicity following thiopurine treatment.
57. Schütz, E., Gummert, J., Armstrong, V. W., Mohr, F. W. & Oellerich, M. Azathioprine pharmacogenetics: the relationship between 6-thioguanine nucleotides and thiopurine methyltransferase in patients after heart and kidney transplantation. Eur. J. Clin. Chem. Clin. Biochem. 34, 199-205 (1996).
58. Allison, A. C. & Eugui, E. M. Mycophenolate mofetil and its mechanism of action. Immunopharmacology 47, 85-118 (2000).
59. Brimmel, M., Mendiola, R., Mangion, J. & Packham, G. BAX frameshift mutations in cell lines derived from human haematopoietic malignancies are associated with resistance to apoptosis and microsatellite instability. Oncogene 16, 1803-1812 (1998).
60. Taverna, P., Liu, L., Hanson, A. J., Monks, A. & Gerson, S. L. Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen. Cancer Chemother. Pharmacol. 46, 507-516 (2000).
61. 2/M arrest requires a full complement of the mismatch repair protein hMLH1. EMBO J. 22, 2245-2254 (2003).
62. Matheson, E. C. & Hall, A. G. Assessment of mismatch repair function in leukaemic cell lines and blasts from children with acute lymphoblastic leukaemia. Carcinogenesis 24, 31-38 (2003).
63. Karran, P. Mechanisms of tolerance to DNA damaging therapeutic drugs. Carcinogenesis 22, 1931-1937 (2001).
64. Dervieux, T. et al. Differing contribution of thiopurine methyltransferase to mercaptopurine versus thioguanine effects in human leukemic cells. Cancer Res. 61, 5810-5816 (2001).
65. Dervieux, T. et al. De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo. Blood 100, 1240-1247 (2002).
66. Hartford, C. et al. Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics. Cancer Res. 67, 4965-4972 (2007).
67. Bruls, W. A., Slaper, H., van der Leun, J. C. & Berrens, L. Transmission of human epidermis and stratum corneum as a function of thickness in the ultraviolet and visible wavelengths. Photochem. Photobiol. 40, 485-494 (1984).
68. International Programme on Chemical Safety. Environmental health criteria 160: ultraviolet radiation. International Programme on Chemical Safety [online], 〈http://www.inchem.org/documents/ehc/ehc/ehc160.htm〉 (1994).
69. O'Donovan, P. et al. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 309, 1871-1874 (2005). The authors identified a new product of the photochemical reactions of DNA 6-thioguanine and demonstrated that these reactions might be important in patients on azathioprine.
70. Hemmens, V. J. & Moore, D. E. Photochemical sensitization by azathioprine and its metabolites. I. 6-Mercaptopurine. Photochem. Photobiol. 43, 247-255 (1986).
71. Cadet, J., Sage, E. & Douki, T. Ultraviolet radiation-mediated damage to cellular DNA. Mutat. Res. 571, 3-17 (2005).
72. Shen, H. R., Spikes, J. D., Kopecekova, P. & Kopecek, J. Photodynamic crosslinking of proteins. II. Photocrosslinking of a model protein-ribonuclease A. J. Photochem. Photobiol. B 35, 213-219 (1996).
73. Au, V. & Madison, S. A. Effects of singlet oxygen on the extracellular matrix protein collagen: oxidation of the collagen crosslink histidinohydroxylysinonorleucine and histidine. Arch. Biochem. Biophys. 384, 133-142 (2000).
74. Montaner, B. et al. Reactive oxygen-mediated damage to a human DNA replication and repair protein EMBO Rep. 8, 1074-1079 (2007).
75. Cadet, J., Douki, T., Gasparutto, D. & Ravanat, J.-L. Oxidative damage to DNA: formation, measurement and biochemical features. Mutat. Res. 531, 5-23 (2003).
76. Lehmann, A. R. Replication of damaged DNA by translesion synthesis in human cells. FEBS Lett. 579, 873-876 (2005).
77. Spector, A. Oxidative stress-induced cataract: mechanism of action. FASEB J. 9, 1173-1182 (1995).
78. Wondrak, G. T., Roberts, M. J., Jacobson, M. K. & Jacobson, E. L. Photosensitized growth inhibition of cultured human skin cells: mechanism and suppression of oxidative stress from solar irradiation of glycated proteins. J. Invest. Dermatol. 119, 489-498 (2002).
79. Balasubramanian, D., Du, X. & Zigler, J. S. The reactions of singlet oxygen with proteins, with special reference to crystallins. Photochem. Photobiol. 52, 761-768 (1990).
80. Thomsen, J. B. et al. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells. Cancer 86, 1080-1086 (1999).
81. Relling, M. V. et al. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia 12, 346-352 (1998).
82. Opelz, G. & Henderson, R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. Lancet 342, 1514-1516 (1993).
83. Euvrard, S. et al. Comparative epidemiologic study of premalignant and malignant epithelial cutaneous lesions developing after kidney and heart transplantation. J. Am. Acad. Dermatol. 33, 222-229 (1995). This article reviews the incidences of the most common types of skin cancer in transplant patients.
84. Bordea, C. et al. Skin cancers in renal-transplant recipients occur more frequently than previously recognized in a temperate climate. Transplantation 77, 574-579 (2004).
85. Penn, I. Cancer in the immunosuppressed organ recipient. Transplant Proc. 23, 1771-1772 (1991).
86. Euvrard, S., Kanitakis, J. & Claudy, A. Skin cancers after organ transplantation. N. Engl. J. Med. 348, 1681-1691 (2003).
87. Mullen, D. L., Silverberg, S. G., Penn, I. & Hammond, W. S. Squamous cell carcinoma of the skin and lip in renal homograft recipients. Cancer 37, 729-734 (1976).
88. Penn, I. The problem of cancer in transplant patients: an overview. Transplant. Sci. 4, 23-32 (1994).
89. Young, A. R. & Walker, S. L. Effects of solar simulated radiation on the human immune system: influence of phototypes and wavebands. Exp. Dermatol. 11 (Suppl. 1), 17-19 (2002).
90. Hanneman, K. K., Cooper, K. D. & Baron, E. D. Ultraviolet immunosuppression: mechanisms and consequences. Dermatol. Clin. 24, 19-25 (2006).
91. Warren, D. J., Andersen, A. & Slordal, L. Quantitation of 6-thioguanine residues in peripheral blood leukocyte DNA obtained from patients receiving 6-mercaptopurine-based maintenance therapy. Cancer Res. 55, 1670-1674 (1995).
92. Cuffari, C., Li, D. Y., Mahoney, J., Barnes, J. Y. & Bayless, T. M. Peripheral blood mononuclear cell DNA 6-thioguanine metabolite levels correlate with decreased interferon-γ production in patients with Crohn's disease on AZA therapy. Dig. Dis. Sci. 49, 133-137 (2004).
93. Baumgart, D. C. & Carding, S. R. Inflammatory bowel disease: cause and immunobiology. Lancet 369, 1627-1640 (2007).
94. Bernstein, C. N., Blanchard, J. F., Kliewer, E. & Wajda, A. Cancer risk in patients with inflammatory bowel disease. Cancer 91, 854-862 (2001).
95. Masunaga, Y. et al. Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease. Ann. Pharmacother. 41, 21-28 (2007).
96. Seril, D. N., Liao, J., Yang, G.-Y. & Yang, C. S. Oxidative stress and ulcerative colitis-associated carcinogenesis: studies in humans and animal models. Carcinogenesis 24, 353-362 (2003).
97. Lee, D.-H., Esworthy, R. S., Chu, C., Pfeifer, G. P. & Chu, F.-F. Mutation accumulation in the intestine and colon of mice deficient in two intracellular glutathione peroxidases. Cancer Res. 66, 9845-9851 (2006).
98. Weinshilboum, R. M. & Sladek, S. L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. 32, 651-662 (1980).
99. Naughton, M. A., Battaglia, E., O'Brien, S., Walport, M. J. & Botto, M. Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine. Rheumatology 38, 640-644 (1999).
100. Savani, F. A., Prosser, C., Bailey, R. J., Jacobs, P. & Fedorak, R. N. Thiopurine methyltransferase enzyme activity determination before treatment of inflammatory bowel disease with azathioprine: effect on cost and adverse events. Can. J. Gastroenterol. 19, 147-151 (2005).
101. Dubinsky, M. C. et al. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am. J. Gastroenterol. 100, 2239-2247 (2005).
102. Anstev, A. V., Wakelin, S. & Reynolds, N. J. Guidelines for prescribing azathioprine in dermatology. Br. J. Dermatol. 151, 1123-1132 (2004).